• 7 June 2013

    Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm. Other investors include Neomed and Initiative Capital Romandie.

  • 22 May 2013

    JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today its first interim results of the JenaValve Evaluation of Long Term Performance and Safety In Patients with Severe Aortic Stenosis (JUPITER) Registry at EuroPCR in Paris. JUPITER is a post-market registry to evaluate five-year long term safety and effectiveness of the 2nd generation transapical JenaValve TAVI system in 180 elderly high-risk patients. The consecutive enrollment of the patients ensures that the patient population represents a real world clinical use of the device. All serious adverse events were source data verified. Major adverse events were adjudicated by an independent medical reviewer.

  • 16 May 2013

    Sonendo®, a developer of a revolutionary technology for the endodontic marketplace, unveiled its new Multisonic Ultracleaning™ System at the recent American Association of Endodontists (AAE) in Hawaii, a national, member-based organization dedicated to endodontic education.

  • 13 May 2013

    Endosense, a pioneer and leader in contact force (CF) technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, further advanced its leadership position in the field with new study data validating the importance of several proprietary contact force parameters, including its most recently developed Lesion Index (LSI™). Unveiled in abstracts at the Heart Rhythm 2013 held last week in Denver, the data also demonstrated the ability of the company’s TactiCath® ablation catheter to detect excessive contact force during robotic catheter navigation.

  • 10 May 2013

    Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis’ LSE (Low Systemic Exposure) technology that creates ‘topical-by-design’ drugs.